Innate Pharma's Upcoming Conference Call for Q3 2024
Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) has revealed its plans to hold an important conference call aimed at discussing its business progress during the third quarter of 2024. This engaging session is scheduled to take place on a Wednesday at 2 p.m. CET / 8 a.m. ET.
Meet the Leadership Team
The call will feature several key executives from Innate Pharma, including:
- Jonathan Dickinson, Chief Executive Officer
- Sonia Quaratino, Executive Vice President, Chief Medical Officer
- Yannis Morel, Executive Vice President, Chief Operating Officer
- Frédéric Lombard, Senior Vice President, Chief Financial Officer
- Arvind Sood, Executive Vice President, President of US Operations
Accessing the Virtual Event
The live webcast will ensure that all interested parties can join in. Detailed information on accessing the event will be readily available on the Innate Pharma website's investor section.
For those who prefer to join via telephone, a registration link will also be provided to facilitate participation by phone.
Engaging with Innate Pharma
Those unable to attend the live event can look forward to a replay of the webcast, which will be made accessible on the company’s website for a duration of 90 days post-event.
About Innate Pharma
Innate Pharma S.A. stands out as a prominent biotechnology company at the forefront of developing immunotherapies specifically designed for cancer patients. With a focus on harnessing the innate immune system, the company employs innovative techniques including monoclonal antibodies and multi-specific NK cell engagers through their proprietary ANKET platform. Their portfolio prominently features the lead proprietary program, lacutamab, alongside collaborations for developing monalizumab with AstraZeneca for non-small cell lung cancer.
Innate Pharma's commitment to developing therapies extends to several promising ANKET drug candidates for diverse tumor types and IPH4502, a unique ADC targeting solid tumors.
Partnerships and Collaborations
In its journey, Innate Pharma has established robust partnerships with respected biopharmaceutical firms such as Sanofi and AstraZeneca. Furthermore, the company collaborates with eminent research institutions to foster innovation and development, significantly benefiting patients in need.
Company Shares and Tickers
The shares of Innate Pharma S.A. are publicly traded, providing an opportunity for investors to engage with a dynamic company dedicated to medical advancements in oncology. The firm is listed on Euronext Paris and also on Nasdaq under the ticker IPHA, highlighting its presence in the global financial arena.
Connecting with Innate Pharma
To stay informed about Innate Pharma’s latest initiatives, please visit their website and follow the company on various social media platforms. This engagement not only sheds light on their innovative approaches but also keeps interested parties updated on future developments.
Frequently Asked Questions
What is the purpose of the conference call on November 13, 2024?
The conference call will update stakeholders on Innate Pharma's business progress and performance in Q3 of 2024.
Who are the key executives participating in the call?
Key executives include Jonathan Dickinson, Sonia Quaratino, Yannis Morel, Frédéric Lombard, and Arvind Sood.
How can I access the live webcast?
The live webcast will be available through the Innate Pharma Investor section on their website.
Is there a replay of the webcast available?
Yes, a replay will be accessible on the company’s website for 90 days following the event.
What are some of the key programs Innate Pharma is developing?
Innate’s key programs include lacutamab for certain types of lymphomas, monalizumab for lung cancer, and several ANKET drug candidates.
